Glucagon-like Peptide 1 (GLP-1) and Endothelial Dysfunction in Metabolic Syndrome
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Glucagon-like peptide 1 (GLP-1) is an intestinal peptide hormone secreted in a
nutrient-dependent manner that stimulates the pancreatic beta cells to secrete more insulin
in response to the same amount of blood glucose. In patients with Type 2 diabetes, GLP-1
secretion is lower than normal, thus suggesting that the hormone may contribute to the
pathogenesis of the disease. Whether infusion of GLP-1 affects endothelial function and
glucose uptake in humans has never been investigated. In the current proposal, the
investigators hypothesize that GLP-1 administration might ameliorate endothelial dysfunction
in patients with metabolic syndrome. To test this hypothesis, the investigators will evaluate
the acute effects of GLP-1 in the forearm circulation of patients with metabolic syndrome
during local hyperinsulinemia by use of the forearm perfusion technique.